Head-to-head · free
MiniMed Group, Inc. vs Moderna
MMED vs MRNA — return on capital, cash generation, margins and balance sheet side by side.
MMED
6 / 8
measures where MMED leads
MRNA
2 / 8
measures where MRNA leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | MMED · FY2026 | MRNA · FY2025 |
|---|---|---|
| Revenue | $3.1B | $1.9B |
| Net income | (333.0M) | (2.8B) |
| Revenue growth (yearly, multi-year) | — | -43.0% |
| Free cash flow | (420.0M) | (2.1B) |
| Free cash flow margin | -13.5% | -106.2% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -9.6% | -28.9% |
| Gross margin | 54.2% | 54.8% |
| Operating margin | -5.1% | -159.9% |
| Net debt / EBITDA | 4.74x | 0.70x |
Figures are as reported by each company; latest fiscal year shown.
Where MiniMed Group, Inc.'s cash went (FY2026)
- Capital spending
- $223.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Moderna's cash went (FY2025)
- Capital spending
- $192.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free